Femme et Homme
- | Pays :
- United States
- | Organes : -
- | Spécialités : -
Extrait
The objective of this study is to provide access to cabozantinib for eligible subjects with medullary thyroid cancer (MTC) pending approval of Exelixis' New Drug Application (NDA) by the FDA and commercial availability of cabozantinib.
Critère d'inclusion
- Medullary Thyroid Cancer